“Ulcerative Colitis Pipeline Insight, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Ulcerative Colitis Market.
The Ulcerative Colitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.
The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Ulcerative Colitis Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights about emerging therapies for the treatment of Ulcerative Colitis and the aggregate therapies developed by major pharma companies.
-
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ulcerative Colitis Treatment.
-
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Ulcerative Colitis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Ulcerative Colitis Therapeutics Outlook
Ulcerative colitis (UC) is a chronic inflammatory condition associated with rectal bleeding and urgency, tenesmus, and diarrhea. Several medical therapies can be used in the treatment of UC. The primary goals of therapy for patients with UC are to induce remission, maintain remission (i.e., minimize the risk of relapse), and enhance the quality of life.
Ulcerative Colitis treatment depend on the severity of the disease and the symptoms. Each person experiences ulcerative colitis differently, so healthcare providers adjust treatments to improve the person’s symptoms and induce, or bring about, remission.
As per DelveInsight, the dynamics of the Ulcerative Colitis therapeutics market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and also expects the launch of emerging therapies.
DelveInsight’s Report covers around 110+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I), along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Learn How the Ongoing Clinical & Commercial Activities will Affect the Ulcerative Colitis Therapeutic Segment:
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-pipeline-insight
Ulcerative Colitis Therapeutics Landscape
There are approx. 110+ key companies which are developing therapies for Ulcerative Colitis. Currently, Gilead Sciences has its Ulcerative Colitis drug candidates in the most advanced stage of clinical development.
The Key Companies in the Ulcerative Colitis Market include:
Eli Lilly and Company, Lipid Therapeutics, Hoffmann-La Roche, Arena Pharmaceuticals, InDex Pharmaceuticals, EA Pharma, Theravance Biopharma, Boehringer Ingelheim, Janssen Research & Development, Lycera, LG Chem, Iltoo Pharma, Immunic, Hutchison Medipharma, Tianjin Hemay Pharmaceutical, GlaxoSmithKline, Galapagos, Celgene, Gossamer Bio, Eisai, UCB, Suzhou Connect Biopharmaceuticals, Landos Biopharma, Seres Therapeutics, Abivax, Genentech, ParaTech A/S, I-Mab Biopharma, Sublimity Therapeutics Holdco, Reistone Biopharma, Qu Biologics, PurGenesis Technologies, Protagonist Therapeutics, Pfizer, Palobiofarma, Novartis Pharmaceuticals, Bristol-Myers Squibb, Bridge Biotherapeutics, Amgen, Allergan, Applied Molecular Transport, AbGenomics International, Protalix BioTherapeutics, LTT Bio-Pharma Co Ltd, Dongwha pharma, Seres Therapeutics, Innovation Pharmaceuticals, Holy Stone Healthcare, SLA Pharma, OSE Immunotherapeutics, Bridge Biotherapeutics, Mitsubishi Tanabe Pharma, Sterna Biologicals, Mesoblast, Oncostellae, First Wave Bio, Oppilan Pharma, NeuClone, Morphic Therapeutic, Metacrine, LG Chem, Koutif Therapeutics, Kiniksa Pharmaceuticals, Avaxia Biologics, Algernon Pharmaceuticals, Akeso Biopharma, Kaleido Biosciences, Rebiotix, and many more.
Ulcerative Colitis Drugs Analyzed in the report include:
-
Mirikizumab: Eli Lilly and Company
-
Risankizumab: AbbVie
-
Etrasimod: Pfizer
And many more.
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies:
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Ulcerative Colitis Current Treatment Patterns
4. Ulcerative Colitis – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Ulcerative Colitis Late Stage Products (Phase-III)
7. Ulcerative Colitis Mid-Stage Products (Phase-II)
8. Ulcerative Colitis Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Ulcerative Colitis Discontinued Products
13. Ulcerative Colitis Product Profiles
14. Key Companies in the Ulcerative Colitis Market
15. Key Products in the Ulcerative Colitis Therapeutics Segment
16. Dormant and Discontinued Products
17. Ulcerative Colitis Unmet Needs
18. Ulcerative Colitis Future Perspectives
19. Ulcerative Colitis Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
Ulcerative Colitis (UC) Market Forecast and Epidemiology Trends
“Ulcerative Colitis (UC) Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Ulcerative Colitis (UC) Market size, share, and trends in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/